Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. Issue 4 (1st July 2007)

• Record Type: Journal Article
• Authors: Atahan, I. L.; Onal, C.; Ozyar, E.; Yiliz, F.; Selek, U.; Kose, F.
• Is Part Of: International journal of gynecological cancer. Volume 17:Issue 4(2007)
• Page Start: 833
• Page End: 842
• Publication Date: 2007-07-01
• Subjects: brachytherapy -- cervical cancer -- chemoradiotherapy -- prognostic factors -- radiotherapy; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200707000-00013
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : This study evaluates treatment outcomes and possible prognostic factors of inoperable cervical cancer patients treated with external beam radiotherapy (EBRT) and high–dose rate brachytherapy (HDR BRT). Between 1993 and 2000, 183 patients with cervical cancer were treated at our institute. Radiotherapy was the sole treatment modality until January 1997; after the announcement of National Cancer Institute in 1999, 40 mg/m 2 of cisplatin (49%) was routinely applied every week. Median age was 54 years (32–92 years). Most patients (88%) had advanced-stage disease (IIB–IIIB). With a median follow-up time of 45 months (6–121 months), the 5-year overall survival (OS), local recurrence–free survival, disease-free survival (DFS), and distant metastasis–free survival (DMFS) rates were 55%, 71%, 51%, and 77%, respectively. Univariate analysis revealed that age, tumor size, lymph node status, and concomitant cisplatin were prognostic factors for OS. The DFS rates were lower in young age group. Patients with tumor greater than 4 cm and age greater than 40 were at greater risk for local recurrence. Distant metastases were more frequent in patients with adenocarcinoma. Concurrent cisplatin use increases DMFS rates (91% vs 78%; P = 0.05). In multivariate analysis, extensive stage, parametrial infiltration, young age, adenocarcinoma histopathology, and lymph node metastasis were negative prognostic factors for OS while concomitant cisplatin increases OS. Likewise, patients with extensive stage, adenocarcinoma, and without concurrent cisplatin administration had more risk for distant metastasis. There was no treatment-related mortality. Grade 3–4 morbidity rates were seen only in eight patients (4%). The combination of EBRT and HDR BRT together with concomitant chemotherapy in the treatment of locally advanced carcinoma of cervix is safe and well tolerated with acceptable morbidity.